Overview of 99mTc-anti-TNF-α scintigraphy: Diagnostic applications


Creative Commons License

Elboga U., Kalender E., Yalcin H.

Reports in Medical Imaging, vol.7, no.1, pp.1-3, 2014 (Scopus) identifier

  • Publication Type: Article / Review
  • Volume: 7 Issue: 1
  • Publication Date: 2014
  • Doi Number: 10.2147/rmi.s39098
  • Journal Name: Reports in Medical Imaging
  • Journal Indexes: Scopus
  • Page Numbers: pp.1-3
  • Keywords: 99mTc tumor necrosis factor-α imaging, mAb, Monoclonal antibodies, Nuclear medicine
  • Hatay Mustafa Kemal University Affiliated: Yes

Abstract

Tumor necrosis factor alpha (TNF-α) has a role in the pathogenesis of several inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. As TNF-α plays a role in the pathogenesis of different inflammatory diseases, anti-TNF-α agents (monoclonal antibodies [mAbs]) such as infliximab, adalimumab, and certolizumab have been developed and investigated for the treatment of these conditions. In recent years, these mAbs also have been used for diagnosis, monitoring, follow-up of disease activity, and therapy decision-making for inflammatory diseases, especially rheumatoid arthritis, after labeling with 99mTc. However, 99mTc-anti-TNF-α imaging might have severe adverse effects and is expensive. In contrast, scintigraphic imaging before therapy with radiolabeled mAbs may be a cost-effective solution for therapy decisions. © 2014 Elboga et al.